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Tuberculosis (TB), caused by Mycobacterium tuberculosis, is endemic in Pakistan. Resistance to 
both firstline rifampicin and isoniazid drugs (multidrug‑resistant TB; MDR‑TB) is hampering disease 
control. Rifampicin resistance is attributed to rpoB gene mutations, but rpoA and rpoC loci may also 
be involved. To characterise underlying rifampicin resistance mutations in the TB endemic province 
of Khyber Pakhtunkhwa, we sequenced 51 M. tuberculosis isolates collected between 2016 and 2019; 
predominantly, MDR‑TB (n = 44; 86.3%) and lineage 3 (n = 30, 58.8%) strains. We found that known 
mutations in rpoB (e.g. S405L), katG (e.g. S315T), or inhA promoter loci explain the MDR‑TB. There 
were 24 unique mutations in rpoA, rpoB, and rpoC genes, including four previously unreported. Five 
instances of within‑host resistance diversity were observed, where two were a mixture of MDR‑TB 
strains containing mutations in rpoB, katG, and the inhA promoter region, as well as compensatory 
mutations in rpoC. Heteroresistance was observed in two isolates with a single lineage. Such 
complexity may reflect the high transmission nature of the Khyber Pakhtunkhwa setting. Our study 
reinforces the need to apply sequencing approaches to capture the full‑extent of MDR‑TB genetic 
diversity, to understand transmission, and to inform TB control activities in the highly endemic setting 
of Pakistan.
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), affects ~ 10 million people  annually1. Despite a 
recent reduction in TB incidence, increasing drug resistance is making infection control  difficult1. New diagnostic 
tools and treatments are needed in developing countries to inform clinical and disease control  activities2. The rec-
ommended combination of anti-TB drugs involves a 6-month standard regimen including first-line rifampicin, 
isoniazid, ethambutol, and  pyrazinamide1. The detection of M. tuberculosis resistant to first-line rifampicin 
(RR-TB) and isoniazid, together called multidrug resistance (MDR-TB), is especially crucial in  Pakistan3. The 
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country is in the top eight for RR-TB and MDR-TB burden, with an estimated 6100 of its > 330,000 TB cases in 
2019 presenting with RR-TB or greater  resistance4.
Khyber Pakhtunkhwa is the third largest province of Pakistan, with an area of 74,521  km2 and a population 
size of approximately 30.5 million individuals. It has a history of armed conflicts, and TB control has been a 
neglected area of public health. Recently, a TB control program was launched at Hayatabad Medical Complex 
Peshawar to monitor disease incidence and perform drug susceptibility testing (DST) to assess levels of RR-TB 
and MDR-TB. RR-TB is mainly caused by the presence of mutations in the RNA polymerase β subunit (rpoB) 
gene. Mutations in an 81-bp core region of the rpoB gene, known as the RR-determining region (RRDR), account 
for 95% of the RR-TB detected in clinical  isolates5. However, secondary mutations in the rpoA or rpoC genes can 
mitigate the initial fitness cost caused by a rpoB  mutation6,7. About one-third of RR-TB involves rpoB mutant 
strains with companion rpoC or rpoA  mutations8. Here, by sequencing fifty-one M. tuberculosis, we aimed to 
summarise the diversity and potential role of rpoB, rpoA, and rpoC mutations in the high MDR incidence setting 
of Khyber Pakhtunkhwa, to inform diagnostics tools for TB control and implementation. The analysis revealed 
some mixed MDR infections and heteroresistance, reflecting the complex dynamics of the high transmission 
setting in Pakistan, and reinforcing the need for robust diagnostic tools.
Materials and methods
A total of 4822 pulmonary and extrapulmonary samples positive for M. tuberculosis were processed between 2016 
to 2019 by the provincial Reference Laboratory for TB at Hayatabad Medical Complex Peshawar. Samples were 
received from all the Programmatic drug management units in the province. All samples were processed using 
the N-acetyl-l-cysteine–sodium hydroxide (NALC–NaOH) concentration method, using Lowenstein–Jensen 
medium (LJ) solid culture and liquid MGIT tubes containing 7H9  media9. All samples were subject to pheno-
typic drug susceptibility testing (DST), performed through the automated BACTEC MGIT 960 system (BD 
Diagnostic Systems, NJ, USA)10. The DST for resistant isolates was repeated for confirmation of drug resistance 
profile. Resistance to isoniazid, rifampicin, and other drugs was assessed through the BACTEC MGIT 960 system, 
with established WHO critical  concentrations11. As per WHO guidelines for MGIT DST, there is only a single 
concentration (1.0 umg/mL) for rifampicin. Fifty-one samples (4 pan-susceptible, 47 drug-resistant, including 
44 MDR-TB) were selected for whole genome sequencing (WGS). The source of genomic DNA was MGIT 
Culture (Liquid Culture) and the same culture generation was used for the phenotypic and genotypic (WGS) 
characterisation. The study was approved by the Institutional Ethics Committee of KUST Kohat and Provincial 
Tuberculosis Reference Laboratory, Khyber Pakhtunkhwa (Ref. no.: PTP/PTRL-408/19). All study participants 
gave informed consent for the collection and use of their biological materials, and all methods were performed 
in accordance with the relevant guidelines and regulations.
Genomic DNA for the fifty-one isolates was extracted using the acetyl trimethylammonium bromide (CTAB) 
 method12. The DNA underwent WGS at the London School of Hygiene and Tropical Medicine (LSHTM) using 
the Illumina MiSeq platform (QIAseq FX DNA Library Kit) with a 151 bp paired-end protocol (v3). The quality of 
the resulting raw sequence data (FASTQ files) was assessed using the FastQC tool (v0.11.8). Reads were trimmed 
using trimmomatic software (v0.39, LEADING:3 TRAILING:3 SLIDINGWINDOW:4:20 MINLEN:36). The 
filtered reads were aligned to the H37Rv genome (Accession No. AL123456.3) using Burrow-Wheeler Aligner 
(BWA)-mem (v0.6)  software13. The GATK tool (HaplotypeCaller v4.1.4.1, -ERC GVCF)14 was used to call single 
nucleotide polymorphisms (SNPs) and insertions and deletions (indels), and the variants were annotated for 
function (e.g. non-synonymous mutations, frameshifts). The M. tuberculosis isolates were profiled for lineage 
and genotypic drug resistance using TB-Profiler software (v3.0.0), which requires a minimum of 10 reads to call 
variants by  default15. Mixed infections were defined as samples with more than one lineage, predicted by TB-
Profiler, and supported by > 200 biallelic genomic positions. Mutations were assigned to the strains by comparing 
their frequency in read coverage to the predicted frequency of the strains in each mixture based on genome-wide 
variants. All results were compared to a mutational database consisting of > 35 k M. tuberculosis spanning all 
lineages and drug resistance  types16. The effects of mutations on RpoA, RpoB, and RpoC protein structures were 
investigated using the DynaMut  server17. In particular, the effects on protein stability (changes in vibrational 
entropy, ΔΔG: kcal/mol) and flexibility (ΔΔSVib: kcal/mol-1.K-1) were assessed using models downloaded from 
the PDB (ID: 6c04). Negative predicted stability changes are destabilising, whilst positive changes are stabilising. 
Consensus genomes were constructed for all isolates using bcftools (v1.9)18. A multiple sequence alignment was 
constructed using the consensus genomes, and phylogenetic reconstruction was performed using iqtree software 
(v1.6.12, -m GTR + G)19.
Results
High quality data was generated for fifty-one isolates with a median of 5,186,316 read pairs per isolate. Trimming 
removed low-quality reads leading to the retention of on average 70.9% of pairs with both reads and 97.2% with 
at least one read. Classification of the reads using Kraken software reported high percentages classified as Myco-
bacterium (median: 99.7%). Mapping of the reads led to an average depth of 216-fold coverage, and 99% of the 
genome with at least tenfold coverage. Of the fifty-one M. tuberculosis isolates, the majority were from lineage 3 
(30, 58.8%), and were sourced from female patients (n = 29, 56.9%) and previously treated cases (n = 30, 58.8%) 
(Table 1). We identified four mixed infections, consisting of different sub-lineages (4.8 and 2.2.1, 4.9 and 3, 3 and 
2.2.1, 3 and 4.6.2.1) (Table 1; Supplementary Table S1; Fig. 1), potentially reflecting the high transmission setting. 
By comparing the allelic frequencies at each mutation position with the predicted frequency of the strains within 
a mixture, we assigned mutations to the individual strains wherever possible. The phenotypic and genotypic 
drug resistance profiles were concordant across all samples at the dominant strain level, but the genomic data 
revealed the complexity of the four mixed lineage infections. In particular, one sample contained a combination 
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of MDR-TB and isoniazid-resistant strains, whilst the other three isolate samples were combinations of MDR-TB 
with MDR-TB (n = 2) or pan susceptible (n = 1) strains (Supplementary Table S1).
Isolates with isoniazid resistance (n = 45) presented with underlying haplotypes katG S315T (31/45), 
fabG1 − 15C > T + katG S315T (6/45), fabG1 − 15C > T (3/45), fabG1 − 15C > T + ahpC − 54C > T (3/45), fabG1 
− 15C > T + katG D311G (1/45), and katG V1A (1/45) (Supplementary Table S1). The RR-TB and MDR-TB 
isolates (n = 46) all had established rifampicin related mutations: rpoB S450L (41/46), R552 (3/46), H445D/L/R 
(3/46), S874Y (3/46), and S450W/F (2/46) (Table 2). We found two potential new mutations in rpoB (K891Q, 
P471R) (Table 2), but they appeared on the same background as established resistance markers (rpoB H445L and 
S450L) (Table 3; Supplementary Table S1). Of the RR-TB and MDR-TB samples (n = 46), 34 (73.9%) had at least 
one potential compensatory mutation, the majority in rpoC (32/46) and a minority in rpoA (5/46), including three 
isolates with mutations in both genes. The most common rpoC mutations were V483G (10), E1092D (9), I491T 
(7), V483A (4), P1040S (3), and K891Q (2), and when observed previously, have been present in predominantly 
RR-TB strains (Table 2), thereby reflecting their potential compensatory role. The rpoA mutations included 
D253Y (2/46), V183G (2/46), and D190E (1/46), all appearing to be previously unreported (Table 2), but only 
V183G was present on the background without rpoC mutations (Table 3). Interestingly, the only potentially 
unreported rpoC mutation (V517E) was in a mixed infection (MDR-TB/isoniazid-resistant) with rpoB S450W 
and rpoA D190E present (Table 3, Supplementary Table S1).
We assessed in silico the impact of eight low frequency mutations (rpoB P471R, R552L, S874Y, K891Q; rpoA 
V183G, D190E; rpoC G332, V517E) on the stability and flexibility of appropriate protein structures (RpoA, RpoB, 
RpoC) (Table 4; Figs. 2, 3, 4). These mutations all have low frequency in our study (1–3 isolates) and in the 35 k 
dataset (< 30 isolates). Note, the impact of the potentially unreported rpoA D253Y mutation was not assessed, as 
residues of D253 for RpoA could not be modelled because of the eight mutations considered, all but two (rpoB 
R552L; rpoA D190E) had a potentially stabilizing effect. The rpoC G332R mutation had the highest stability 
and lowest flexibility effects (Table 4) and is found exclusively in RR-TB strains (Table 2). The rpoA D190E led 
to the least stable and highest flexibility effects. This mutation was present on the uncommon rpoB S450W and 
rpoC V517E mutation background, where each mutation is found almost exclusively in RR-TB strains (Table 2).
Discussion
Resistance to rifampicin (RR-TB) has been associated with mutations in an 81 bp hot-spot region of the rpoB 
gene. However, mutations in rpoA and rpoC, have also been linked to RR-TB, particularly in a compensatory 
 role20. We identified 24 mutations across rpoA, rpoB and rpoC genes in 51 M. tuberculosis (46 RR-TB) isolates, 
including six mutations [rpoA (2), rpoB (3), and rpoC (1)], which were not found in a large collection (~ 35 k) 
of global clinical isolates. All RR-TB could be explained by known mutations, including the rpoB S450L (41/46 
isolates), which is the most prevalent mutation globally (~ 64%)20 and in Pakistan (~ 74%21; ~ 71%22). Four rpoB 
mutations (R552L, S874Y, K891Q, P471R) appear not to have been reported by recent genetic studies from 
Table 1.  Patient demographic and genotypic data of the 51 M. tuberculosis isolates. DST drug susceptibility 
test, MDR-TB multidrug-resistant TB. a There are five mixed infections, with three mixed lineage and two same 
lineage infections (see Supplementary Table S1). b MDR-TB or MDR-TB+, with 5 mixed infections involving 
MDR-TB (see Supplementary Table S1).
Characteristic # %
Patient treatment history
Never treated 3 5.9
On treatment 11 21.6












Mixed lineage 3 5.9
Phenotypic/genotypic DST
Susceptible 4 7.8
Rifampicin resistant 2 3.9
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Khyber  Pakhtunkhwa21–23. Some recently reported rpoB mutations in Pakistan (L430P, H445P/Y,  L452P21; S450Q, 
P454H,  G455D22;  D435G21,22,  D435Y21,23), which are of much lower frequency than the S450L mutation and 
sometimes reported in combination with it, were not present in our RR-TB isolates. Similarly, all isoniazid resist-
ance could be explained by known mutations, including the katG S315T (37/45), which has a high frequency 
globally (~ 75%) and in Pakistan (> 89%21,23). The majority of RR-TB/MDR-TB isolates had mutations in rpoC 
(32/46), which is a locus known to restore the fitness of rifampicin-resistant bacteria carrying mutations in 
rpoB24. Other studies have found a lower prevalence of rpoC mutations in MDR isolates (< 30%)6,25,26, including 
a study in  Pakistan26, and inconsistencies may be due to differences in sampling sites and strategies. Eight muta-
tions in rpoC (G332R, N416S, V483A, V517E/L, G594E, P1040S, E1092D) appear not to have been reported in 
recent genetic studies from Khyber  Pakhtunkhwa21–23. The evidence for a prominent compensatory role of rpoA 
in RR-TB is less strong. Our study identified only three rpoA mutations, of which two appear not to have been 
reported before, and were in the presence of rpoC mutations. In general, potential rpoA and rpoC compensatory 
mutations and mechanisms need to be validated experimentally in fitness studies, or through large-scale studies 
involving phylogenetic analysis of longitudinally collected strains.
Phenotypic DST is considered to be the gold standard method to infer resistance. However, some studies 
have reported that liquid culture systems (e.g. the MGIT platform) often fail to detect low-levels of RR-TB27,28, 
including those involving H445D/L/R  mutations27,29, which have been linked to treatment failure or  relapse30–32. 
The role of such mutations can be investigated using protein structural  analysis33, and previous studies have 
shown that mutations may affect the structural dynamics of proteins, making them weak targets, resulting in drug 
 resistance4,34,35. Our in silico analysis revealed that the rpoC G332R mutation, which is rare (< 0.05%) globally 
and exclusively in RR-TB isolates, led to high protein stability and less flexibility, which may be favorable features 
for compensatory effects. This mutation has been previously reported in a South African  setting5, where it was 
observed to originate through homoplastic evolution and thus likely to confer a selective advantage. Several of 
the other low-frequency mutations in the three genes have been reported previously (rpoB  R552L36, rpoB  S874Y37 
and rpoA  V183G6) in different settings and have been proposed as potential compensatory mutations. For other 
low-frequency mutations including rpoB K891Q, rpoB P471R, rpoC V517E, rpoA D190E and rpoA D253Y, we 
Figure 1.  Phylogenetic tree of M. tuberculosis strains (n = 51), with their lineages, multi-drug resistance profiles 
and specific mutations in rpoB, rpoA, and rpoC. The phylogenetic tree was created using a maximum likelihood 
approach. The first vertical band to the right of the tree denotes the lineage. The second vertical band denotes 
the drug resistance phenotype. The squares show the presence of a specific mutation.
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Table 2.  Non-synonymous mutations in rifampicin candidate genes of M. tuberculosis. Bolded are unreported 
by Napier et al. (~ 35 k). RR-TB rifampicin-resistant TB, P polar, NP non-polar, HP hydrophilic, HB 
hydrophobic. a From Napier et al. (~ 35 k).
Gene Nucleotide Mutation Freq Global # (% RR-TB)a P/NP HP/HB
rpoB 761155 S450L 41 5395 (99) P-NP HP-HB
rpoC 764817 V483G 10 473 (98) NP-NP HB-HB
rpoC 766645 E1092D 9 1462 (78) P-P HP-HP
rpoC 764,841 I491T 7 125 (100) NP-P HB-HP
rpoC 764817 V483A 4 154 (99) NP-NP HB-HB
rpoB 761461 R552L 3 27 (100) P-NP HP-HB
rpoB 762427 S874Y 3 14 (100) P-P HP-HP
rpoC 766487 P1040S 3 79 (98) NP-P HB-HP
rpoB 762477 K891Q 2 0 (–) P-P HP-HP
rpoC 764918 V517L 2 55 (100) NP-NP HB-HB
rpoA 3877751 D253Y# 2 0 (–) P-P HP-HP
rpoA 3877960 V183G 2 0 (–) NP-NP HB-HB
rpoB 761110 D435V 1 627 (99) P-NP HP-HB
rpoB 761139 H445D 1 322 (100) P-P HP-HP
rpoB 761140 H445L 1 106 (96) P-NP HP-HB
rpoB 761140 H445R 1 107 (96) P-P HP-HP
rpoB 761155 S450W 1 142 (96) P-NP HP-HB
rpoB 761218 P471R 1 0 (–) NP-P HB-HP
rpoC 764363 G332R 1 59 (100) NP-P HB-HP
rpoC 764,616 N416S 1 30 (100) P-P HP-HP
rpoC 764919 V517E 1 0 (–) NP-P HB-HP
rpoC 765150 G594E 1 4582 (27) NP-P HB-HP
rpoA 3877938 D190E 1 0 (–) P-P HP-HP
rpoB 761155/761156 S450F 1 46 (100) P-NP HP-HB
Table 3.  Combinations of rpoB, rpoC, and rpoA mutations present in the 51 M. tuberculosis isolates. – Absent, 
() proportion of reads in a mixed infection and < 1. a Rifampicin susceptible. b Mixed infections.
rpoB mutations rpoC mutations rpoA mutations # isolates
S450L V483G – 8
S450L I491T, E1092D – 5
– – – 5a
S450L V483A – 4
S450L – – 3
S450L P1040S – 3
S450L V517L – 2
S450L, K891Q – – 2
S450L I491T, E1092D D253Y 2
S450L, S874Y – – 2
S450L – V183G 2
S450L G594E – 1
S450L N416S – 1
S450L G332R – 1
S450L, R552L – – 1
H445L, P471R – – 1
D435V – – 1
S450L, S874Y (0.67) V483G (0.41) – 1
S450L, R552L (0.88) – – 1
S450W (0.42) V517E (0.44) D190E (0.54) 1
S450L (0.21) E1092D (0.20) – 1b
H445R (0.89) – – 1b
H445D (0.34), S450F (0.70) E1092D (0.48) – 1b
S450L, R552L (0.66) V483G (0.27) – 1b
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did not find any previous reports in the literature. These mutations fall outside the rifampicin resistance deter-
mining regions and co-occur with known resistance mutations, potentially to compensate for the fitness impact 
of the resistance mutations.
A potential limitation of the phenotypic DST exposed by our genomic analysis is its robustness to mixed 
infections and heteroresistance. Only the WHO recommended concentration of the rifampicin drug was assessed, 
and dominant rifampicin resistance mutants within MDR-TB mixes can complicate the phenotypic interpretation 
of any low-level rifampicin resistance mutants. In our study, five instances of within-host resistance mechanism 
diversity were observed as the result of mixed infections. Three instances involved mixed-lineage infections, two 
of which were a mixture of MDR-TB strains and one was a mixture of a pan-susceptible and an MDR-TB strain. 
Interestingly, the MDR-TB mixtures contained different resistance-conferring mutations in rpoB, katG and the 
inhA promoter region, as well as likely compensatory mutations in rpoC and potentially rpoA. These mutations 
were found in the same proportions within the raw data as lineage variants, indicating the different strains carry 
resistance markers. Heteroresistance was also observed in isolates with a single lineage. This observation could be 
indicative of acquired resistance, where mutations have not become fixed in the within-host bacterial population. 
Almost all single-lineage RR-TB isolates contained the rpoB S450L at a completely fixed level in the sequenced 
population. Some of these strains possessed additional mutations in rpoB, rpoC and rpoA at unfixed proportions 
(e.g. rpoB R552L, rpoB S874Y, rpoC V483G and rpoA D190E). Based on this observation it is likely that these 
mutations were acquired after the rpoB S450L, which confers high-level resistance and serve as compensatory 
mutations to restore the fitness penalty of the resistance mutation.
Table 4.  Protein structure stability and flexibility effects for low frequency mutations. Low frequency 
mutations from Table 2, where the number of samples with that mutation in the 35 k dataset was < 300. 
a Mutation bolded if potentially unreported; P polar, NP non-polar, HP hydrophilic, HB hydrophobic. b Total 
energy (ΔΔG: kcal/mol), where +ve values are stabilizing and −ve values are destabilizing. c ΔΔSVib ENCoM 
(kcal/mol-1.K-1), where negative values reflect decreasing molecule flexibility; note, residues of D253 have not 
been modelled in PDB structure (PDB ID: 6c04).
Gene Mutationa Freq P/NP HP/HB Energyb Flexibilityc
rpoB R552L 3 P-NP HP-HB − 0.123 − 0.008
rpoB S874Y 3 P-P HP-HP 0.776 − 0.188
rpoB K891Q 2 P-P HP-HP 0.270 − 0.397
rpoA V183G 2 NP-NP HB-HB 0.063 − 0.908
rpoB P471R 1 NP-P HB-HP 0.682 − 0.443
rpoC G332R 1 NP-P HB-HP 1.196 − 3.975
rpoC V517E 1 NP-P HB-HP 0.120 − 0.162
rpoA D190E 1 P-P HP-HP − 0.500 0.104
Figure 2.  Effect of the rpoC G332R and V517E point mutations on RpoC protein dynamics. ΔΔG; Free energy 
difference. ΔΔSVib ENCoM; vibrational entropy energy. The effects have been predicted through the DynaMut 
online server. The increasing (red) and decreasing (blue) molecular flexibility effects of point mutations have 
been depicted. The total energy calculated for mutations shows a stabilizing effect on protein structure.
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The application of sequencing technologies in TB endemic regions will assist clinical management and per-
sonalised anti-TB drug approaches, as well as disease control through surveillance activities. The management of 
MDR-TB strains is essential for the control of TB. In our study, we found that the mutations underlying MDR-TB 
are established variants. Known and putative drug resistance markers in established loci are detectable using 
low-cost sequencing-based approaches (e.g. amplicon-based), suitable for a low resource setting. These methods 
are also robust to mixed infections and  heteroresistance35,38, which were present in our study and likely driven 
by the high transmission setting. Large-scale approaches using whole genome sequencing and analysis will assist 
with understanding the epidemiology and risk groups or factors underpinning the transmission of TB, as well 
as provide insights into drug resistance and compensatory mechanisms. Such insights will inform the deploy-
ment of anti-TB drug regimens and disease control tools and strategies in high burden settings, such as Pakistan.
Conclusion
Whole genome sequencing for TB clinical management and disease control will have the greatest benefit in 
complex community outbreaks in endemic regions. Our study in the Khyber Pakhtunkhwa province in Pakistan 
has provided a characterization of circulating rifampicin resistance and MDR-TB mutations. Such insights will 
Figure 3.  Effects of R552L, S874Y, and K891Q mutations on the RpoB protein structure. ΔΔG; Free energy 
difference. ΔΔSVib ENCoM; vibrational entropy energy. The increasing (red) and decreasing (blue) molecular 
flexibility effects of point mutations have been depicted.
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assist sequencing-informed diagnosis for proactive TB patient management, and the deployment of anti-TB 
drug regimens and surveillance activities.
Data availability
The raw sequence data is available from the EBI ENA (Accession number PRJEB43284).
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